TG Therapeutics saw an improvement in its IBD SmartSelect Composite Rating Wednesday, from 94 to 96.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The new score indicates the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The best stocks tend to have a 95 or better grade as they start a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
TG Therapeutics is now out of buy range after clearing the 36.84 buy point in a consolidation.
One weak spot is the company's 37 EPS Rating, which tracks quarterly and annual earnings-per-share growth. Look for that to improve to 80 or better to show it's in the top 20% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 0% increase in earnings for Q4. Sales growth climbed 146%, up from -49% in the prior quarter. That marks one quarter of increasing revenue increases. The company's next quarterly report is expected on or around May. 6.
TG Therapeutics holds the No. 6 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly-rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
